Registered number
14620688
BlackfinBio Limited
Unaudited Filleted Accounts
31 December 2024
BlackfinBio Limited
Registered number: 14620688
Balance Sheet
as at 31 December 2024
Notes 31/12/24 31/1/24
£ £
Fixed assets
Investments 3 628 628
Current assets
Debtors 4 590,214 1,298,325
Cash at bank and in hand 96,682 249,998
686,896 1,548,323
Creditors: amounts falling due within one year 5 (152,401) (431,077)
Net current assets 534,495 1,117,246
Net assets 535,123 1,117,874
Capital and reserves
Called up share capital 239 239
Share premium 2,749,872 2,749,872
Profit and loss account (2,214,988) (1,632,237)
Shareholders' funds 535,123 1,117,874
The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.
The members have not required the company to obtain an audit in accordance with section 476 of the Act.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.
Peter John Nolan
Director
Approved by the board on 26 September 2025
BlackfinBio Limited
Notes to the Accounts
for the period from 1 February 2024 to 31 December 2024
1 Accounting policies
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenues from partner license agreements when it has met contractual milestones and turnover from the milestone is fixed and has been earned.
Investments
Investments in subsidiaries, associates and joint ventures are measured at cost less any accumulated impairment losses. Listed investments are measured at fair value. Unlisted investments are measured at fair value unless the value cannot be measured reliably, in which case they are measured at cost less any accumulated impairment losses. Changes in fair value are included in the profit and loss account.
Debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Taxation
A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.

The company is entitled, where applicable, to claim Research & Development (“R&D”) tax credits in respect of qualifying expenditure. R&D tax credits are recognised in the income statement.
Provisions
Provisions (ie liabilities of uncertain timing or amount) are recognised when there is an obligation at the reporting date as a result of a past event, it is probable that economic benefit will be transferred to settle the obligation and the amount of the obligation can be estimated reliably.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
2 Employees 31/12/24 31/1/24
Number Number
Average number of persons employed by the company 0 0
3 Investments
Investments in
subsidiary
undertakings
£
Cost
At 1 February 2024 628
At 31 December 2024 628

In the prior period the company set up a wholly owned US subsidiary, BlackfinBio USA, LLC.
4 Debtors 31/12/24 31/1/24
£ £
Amounts owed by group undertakings and undertakings in which the company has a participating interest 513,010 1,298,214
Unpaid share capital 111 111
Other debtors 77,093 -
590,214 1,298,325
5 Creditors: amounts falling due within one year 31/12/24 31/1/24
£ £
Trade creditors 75,160 -
Accruals 77,241 431,077
152,401 431,077
6 Controlling party
There is no overall controlling party.
7 Other information
BlackfinBio Limited is a private company limited by shares and incorporated in England. Its registered office is:
197-201 Manchester Road
West Timperley
Altrincham
Cheshire
WA14 5NU
BlackfinBio Limited 14620688 false 2024-02-01 2024-12-31 2024-12-31 VT Final Accounts July 2024 Peter John Nolan No description of principal activity 14620688 2023-01-27 2024-01-31 14620688 core:WithinOneYear 2024-01-31 14620688 core:ShareCapital 2024-01-31 14620688 core:SharePremium 2024-01-31 14620688 core:RetainedEarningsAccumulatedLosses 2024-01-31 14620688 2024-02-01 2024-12-31 14620688 bus:PrivateLimitedCompanyLtd 2024-02-01 2024-12-31 14620688 bus:AuditExemptWithAccountantsReport 2024-02-01 2024-12-31 14620688 bus:Director40 2024-02-01 2024-12-31 14620688 1 2024-02-01 2024-12-31 14620688 2 2024-02-01 2024-12-31 14620688 countries:England 2024-02-01 2024-12-31 14620688 bus:FRS102 2024-02-01 2024-12-31 14620688 bus:FilletedAccounts 2024-02-01 2024-12-31 14620688 2024-12-31 14620688 core:WithinOneYear 2024-12-31 14620688 core:ShareCapital 2024-12-31 14620688 core:SharePremium 2024-12-31 14620688 core:RetainedEarningsAccumulatedLosses 2024-12-31 14620688 2024-01-31 iso4217:GBP xbrli:pure